ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018
Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- Case-Fatality Risk of Norovirus, England, 2022-2025.Emerging infectious diseases · 2026Article
- Cost-effectiveness and return on investment of 20-valent pneumococcal conjugate vaccine use among adults in England: analysis from the societal perspective.Cost effectiveness and resource allocation : C/E · 2026Article
- Epidemiological pattern and incidence estimation of infectious diarrhea before the COVID-19 pandemic: Beijing, China, 2015-2019.Frontiers in public health · 2026Article
- Current Perspectives and Future Directions in the Immunogenicity Landscape of Norovirus Vaccines.Journal of microbiology and biotechnology · 2025Review
- An application of nowcasting methods: Cases of norovirus during the winter 2023/2024 in England.PLoS computational biology · 2025Article
- Article
- Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?Vaccines · 2023Article
- Review
- Article
- Norovirus outbreak amid COVID-19 in the United Kingdom; priorities for achieving control.Journal of medical virology · 2022Article
- Article
- Effects of patient room layout on viral accruement on healthcare professionals' hands.Indoor air · 2021Article
- Copper as an antimicrobial agent: recent advances.RSC advances · 2021Review
- Differential impact of the COVID-19 pandemic on laboratory reporting of norovirus and Campylobacter in England: A modelling approach.PloS one · 2021Article
- The Clinical and Economic Burden of Norovirus Gastroenteritis in the United States.The Journal of infectious diseases · 2020Article
- Sources of Airborne Norovirus in Hospital Outbreaks.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Challenges of investigating a large food-borne norovirus outbreak across all branches of a restaurant group in the United Kingdom, October 2016.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Article
- Estimating the burden of care home gastroenteritis outbreaks in England, 2014-2016.BMC infectious diseases · 2019Article
- An interactive data visualisation application to investigate nosocomial transmission of infections.Wellcome open research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 2 countries.
Funding
Abstract
Background: Norovirus places a substantial burden on healthcare systems, arising from infected patients, disease outbreaks, beds kept unoccupied for infection control, and staff absences due to infection. In settings with high rates of bed occupancy, opportunity costs arise from patients who cannot be admitted due to beds being unavailable. With several treatments and vaccines against norovirus in development, quantifying the expected economic burden is timely. Methods: The number of inpatients with norovirus-associated gastroenteritis in England was modeled using infectious and noninfectious gastrointestinal Hospital Episode Statistics codes and laboratory reports of gastrointestinal pathogens collected at Public Health England. The excess length of stay from norovirus was estimated with a multistate model and local outbreak data. Unoccupied bed-days and staff absences were estimated from national outbreak surveillance. The burden was valued conventionally using accounting expenditures and wages, which we contrasted to the opportunity costs from forgone patients using a novel methodology. Results: Between July 2013 and June 2016, 17.7% (95% confidence interval [CI], 15.6%‒21.6%) of primary and 23.8% (95% CI, 20.6%‒29.9%) of secondary gastrointestinal diagnoses were norovirus attributable. Annually, the estimated median 290000 (interquartile range, 282000‒297000) occupied and unoccupied bed-days used for norovirus displaced 57800 patients. Conventional costs for the National Health Service reached £107.6 million; the economic burden approximated to £297.7 million and a loss of 6300 quality-adjusted life-years annually. Conclusions: In England, norovirus is now the second-largest contributor of the gastrointestinal hospital burden. With the projected impact being greater than previously estimated, improved capture of relevant opportunity costs seems imperative for diseases such as norovirus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.